Acmucabtagene autoleucel

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAcmucabtagene autoleucel

Drug Alias NameTAC01-CD19TAC-921CD19-TAC01

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTriumvira Immunologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTriumvira Immunologics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A